TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-label Randomized Phase 1 Study to Investigate the Pharmacokinetics and Pharmacodynamics of Subcutaneous and Intravenous Administrations of Golimumab to Subjects With Rheumatoid Arthritis
Brief Summary: This is a Phase 1, pharmacokinetic and pharmacodynamic study of intravenous and subcutaneous administered golimumab in patients with rheumatoid arthritis.


Options:
A: N/A
B: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: Golimumab | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Drug: Golimumab | Intervention Type: DRUG; Name: Golimumab; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: Golimumab; Assigned to Arm(s): 001
C: Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: tocilizumab [RoActemra/Actemra] | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): 1

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-label Randomized Phase 1 Study to Investigate the Pharmacokinetics and Pharmacodynamics of Subcutaneous and Intravenous Administrations of Golimumab to Subjects With Rheumatoid Arthritis
Brief Summary: This is a Phase 1, pharmacokinetic and pharmacodynamic study of intravenous and subcutaneous administered golimumab in patients with rheumatoid arthritis.


Options:
A: Arm Label: 5 mg BID CP-690,550; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: 10 mg BID CP-690,550; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: methotrexate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Disease-modifying antirheumatic drug | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 5 mg BID CP-690,550 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 10 mg BID CP-690,550 | Intervention Type: DRUG; Name: Disease-modifying antirheumatic drug; Assigned to Arm(s): methotrexate
B: Arm Label: Subcutaneous (SC) Abatacept; Type: ACTIVE_COMPARATOR; Interventions: Drug: Subcutaneous (SC) Abatacept | Arm Label: Intravenous (IV) Abatacept; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravenous (IV) Abatacept | Intervention Type: DRUG; Name: Subcutaneous (SC) Abatacept; Assigned to Arm(s): Subcutaneous (SC) Abatacept | Intervention Type: DRUG; Name: Intravenous (IV) Abatacept; Assigned to Arm(s): Intravenous (IV) Abatacept
C: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: Golimumab | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Drug: Golimumab | Intervention Type: DRUG; Name: Golimumab; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: Golimumab; Assigned to Arm(s): 001
D: Arm Label: Sequence 1; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Sequence 2; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Sequence 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: CP-690,550 | Arm Label: Sequence 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: CP-690,550 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Sequence 1 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Sequence 1 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Sequence 2 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Sequence 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Sequence 3 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Sequence 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Sequence 4 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Sequence 4

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Calcium Supplementation for a Healthy Weight (CaSHeW)
Brief Summary: The objective of this study is to investigate the effect of calcium (Ca) and vitamin D (D) supplemented orange juice (OJ) on weight loss and visceral fat mass in overweight and obese adults.


Options:
A: Arm Label: 90 Hz whole-body vibration; Type: EXPERIMENTAL; Interventions: Device: Juvent 1000 Dynamic Motion Therapy (DMT) Platform | Arm Label: 30 Hz whole-body vibration; Type: EXPERIMENTAL; Interventions: Device: Juvent 1000 Dynamic Motion Therapy (DMT) Platform | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Juvent 1000 Dynamic Motion Therapy (DMT) Platform; Assigned to Arm(s): 90 Hz whole-body vibration | Intervention Type: DEVICE; Name: Juvent 1000 Dynamic Motion Therapy (DMT) Platform; Assigned to Arm(s): 30 Hz whole-body vibration
B: Arm Label: OJ fortified with Ca and VitD; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Orange Juice fortified with Calcium and Vitamin D, Behavioral: Nutritional Counseling | Arm Label: OJ without VitD and Ca; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Orange juice without Ca or VitD, Behavioral: Nutritional Counseling | Intervention Type: DIETARY_SUPPLEMENT; Name: Orange Juice fortified with Calcium and Vitamin D; Assigned to Arm(s): OJ fortified with Ca and VitD | Intervention Type: DIETARY_SUPPLEMENT; Name: Orange juice without Ca or VitD; Assigned to Arm(s): OJ without VitD and Ca | Intervention Type: BEHAVIORAL; Name: Nutritional Counseling; Assigned to Arm(s): OJ fortified with Ca and VitD, OJ without VitD and Ca
C: Arm Label: 1; Type: OTHER; Interventions: Drug: Vitamin D3 2,000 IU orally once daily, Drug: Calcium Carbonate 400 mg orally twice daily | Arm Label: 2; Type: OTHER; Interventions: Drug: Vitamin D3 2,000 IU orally once daily, Drug: Calcium-Placebo | Arm Label: 3; Type: OTHER; Interventions: Drug: Calcium Carbonate 400 mg orally twice daily, Drug: Vitamin D3-Placebo | Arm Label: 4; Type: OTHER; Interventions: Drug: Vitamin D3-Placebo, Drug: Calcium-Placebo | Intervention Type: DRUG; Name: Vitamin D3 2,000 IU orally once daily; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Calcium Carbonate 400 mg orally twice daily; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: Vitamin D3-Placebo; Assigned to Arm(s): 3, 4 | Intervention Type: DRUG; Name: Calcium-Placebo; Assigned to Arm(s): 2, 4
D: Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogens; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: progestins; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of Smoking-cessation Interventions for Urban Hospital Patients.
Brief Summary: The investigators plan to compare the effectiveness and cost effectiveness of an inpatient smoking cessation intervention for all smokers hospitalized at two urban public hospitals.


Options:
A: Arm Label: Hospital phone counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Telephone Counseling | Arm Label: Fax-to-quit; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Fax-to-quit | Intervention Type: BEHAVIORAL; Name: Telephone Counseling; Assigned to Arm(s): Hospital phone counseling | Intervention Type: BEHAVIORAL; Name: Fax-to-quit; Assigned to Arm(s): Fax-to-quit
B: Intervention Type: BEHAVIORAL; Name: QuitLink (office support system for quit line referral); Assigned to Arm(s): N/A
C: Arm Label: Proactive outreach; Type: EXPERIMENTAL; Interventions: Behavioral: Proactive outreach | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual care | Intervention Type: BEHAVIORAL; Name: Proactive outreach; Assigned to Arm(s): Proactive outreach | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): Usual care
D: Arm Label: Life Style Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: IVR intervention | Arm Label: Life Counseling; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: IVR control | Intervention Type: BEHAVIORAL; Name: IVR intervention; Assigned to Arm(s): Life Style Counseling | Intervention Type: BEHAVIORAL; Name: IVR control; Assigned to Arm(s): Life Counseling

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of Smoking-cessation Interventions for Urban Hospital Patients.
Brief Summary: The investigators plan to compare the effectiveness and cost effectiveness of an inpatient smoking cessation intervention for all smokers hospitalized at two urban public hospitals.


Options:
A: Arm Label: Standard Care; Type: EXPERIMENTAL; Interventions: Behavioral: Standard Care | Arm Label: Motivational Enhancement; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Enhancement | Intervention Type: BEHAVIORAL; Name: Standard Care; Assigned to Arm(s): Standard Care | Intervention Type: BEHAVIORAL; Name: Motivational Enhancement; Assigned to Arm(s): Motivational Enhancement
B: Arm Label: Web-Based Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Web-Based Tailored Smoking Cessation Intervention | Arm Label: Standard Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Web-Based Tailored Smoking Cessation Intervention, Behavioral: Standard of Care | Intervention Type: BEHAVIORAL; Name: Web-Based Tailored Smoking Cessation Intervention; Assigned to Arm(s): Standard Care, Web-Based Intervention | Intervention Type: BEHAVIORAL; Name: Standard of Care; Assigned to Arm(s): Standard Care
C: Arm Label: Intensive behavioral intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Positively Smoke Free | Arm Label: Standard care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard care | Intervention Type: BEHAVIORAL; Name: Positively Smoke Free; Assigned to Arm(s): Intensive behavioral intervention | Intervention Type: BEHAVIORAL; Name: Standard care; Assigned to Arm(s): Standard care
D: Arm Label: Hospital phone counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Telephone Counseling | Arm Label: Fax-to-quit; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Fax-to-quit | Intervention Type: BEHAVIORAL; Name: Telephone Counseling; Assigned to Arm(s): Hospital phone counseling | Intervention Type: BEHAVIORAL; Name: Fax-to-quit; Assigned to Arm(s): Fax-to-quit

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of Smoking-cessation Interventions for Urban Hospital Patients.
Brief Summary: The investigators plan to compare the effectiveness and cost effectiveness of an inpatient smoking cessation intervention for all smokers hospitalized at two urban public hospitals.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Practice Quit Attempt plus nicotine lozenge | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Practice Quit Attempt only | Intervention Type: OTHER; Name: Practice Quit Attempt plus nicotine lozenge; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Practice Quit Attempt only; Assigned to Arm(s): 2
B: Arm Label: Brief Advice; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Brief Advice (BA) | Arm Label: Motivational Interviewing; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Interviewing (MI) | Arm Label: Health Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Health Education (HE) | Intervention Type: BEHAVIORAL; Name: Brief Advice (BA); Assigned to Arm(s): Brief Advice | Intervention Type: BEHAVIORAL; Name: Motivational Interviewing (MI); Assigned to Arm(s): Motivational Interviewing | Intervention Type: BEHAVIORAL; Name: Health Education (HE); Assigned to Arm(s): Health Education
C: Arm Label: Control (N=25); Type: ACTIVE_COMPARATOR; Interventions: Drug: Transdermal nicotine patch, Behavioral: In-person smoking cessation counseling | Arm Label: Financial rewards (N=25); Type: EXPERIMENTAL; Interventions: Drug: Transdermal nicotine patch, Behavioral: In-person smoking cessation counseling, Behavioral: Contingent financial rewards for smoking abstinence | Arm Label: Text messaging (N=25); Type: EXPERIMENTAL; Interventions: Drug: Transdermal nicotine patch, Behavioral: In-person smoking cessation counseling, Behavioral: Text messages to support smoking abstinence | Intervention Type: DRUG; Name: Transdermal nicotine patch; Assigned to Arm(s): Control (N=25), Financial rewards (N=25), Text messaging (N=25) | Intervention Type: BEHAVIORAL; Name: In-person smoking cessation counseling; Assigned to Arm(s): Control (N=25), Financial rewards (N=25), Text messaging (N=25) | Intervention Type: BEHAVIORAL; Name: Contingent financial rewards for smoking abstinence; Assigned to Arm(s): Financial rewards (N=25) | Intervention Type: BEHAVIORAL; Name: Text messages to support smoking abstinence; Assigned to Arm(s): Text messaging (N=25)
D: Arm Label: Hospital phone counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Telephone Counseling | Arm Label: Fax-to-quit; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Fax-to-quit | Intervention Type: BEHAVIORAL; Name: Telephone Counseling; Assigned to Arm(s): Hospital phone counseling | Intervention Type: BEHAVIORAL; Name: Fax-to-quit; Assigned to Arm(s): Fax-to-quit

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of Smoking-cessation Interventions for Urban Hospital Patients.
Brief Summary: The investigators plan to compare the effectiveness and cost effectiveness of an inpatient smoking cessation intervention for all smokers hospitalized at two urban public hospitals.


Options:
A: Arm Label: Standard Care; Type: EXPERIMENTAL; Interventions: Behavioral: Standard Care | Arm Label: Motivational Enhancement; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Enhancement | Intervention Type: BEHAVIORAL; Name: Standard Care; Assigned to Arm(s): Standard Care | Intervention Type: BEHAVIORAL; Name: Motivational Enhancement; Assigned to Arm(s): Motivational Enhancement
B: Arm Label: Behavioral; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Interviewing Intervention for ETS Reduction | Arm Label: Education Only; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Educational Program for ETS Reduction | Intervention Type: BEHAVIORAL; Name: Motivational Interviewing Intervention for ETS Reduction; Assigned to Arm(s): Behavioral | Intervention Type: BEHAVIORAL; Name: Educational Program for ETS Reduction; Assigned to Arm(s): Education Only
C: Arm Label: Spirometry and lifestyle counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Smoking cessation advice, Behavioral: Spirometry and smoking cessation advice | Arm Label: Lifestyle counseling; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Smoking cessation advice; Assigned to Arm(s): Spirometry and lifestyle counseling | Intervention Type: BEHAVIORAL; Name: Spirometry and smoking cessation advice; Assigned to Arm(s): Spirometry and lifestyle counseling
D: Arm Label: Hospital phone counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Telephone Counseling | Arm Label: Fax-to-quit; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Fax-to-quit | Intervention Type: BEHAVIORAL; Name: Telephone Counseling; Assigned to Arm(s): Hospital phone counseling | Intervention Type: BEHAVIORAL; Name: Fax-to-quit; Assigned to Arm(s): Fax-to-quit

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-label, Phase I/II Trial for Safety and Efficacy Study of Autologous Bone Marrow Derived Stem Cell Treatment in Amyotrophic Lateral Sclerosis
Brief Summary: The purpose of this study is to evaluate the safety and efficacy of autologous bone marrow-derived stem cells("HYNR-CS inj"), through intrathecal delivery for the treatment in patients with ALS.

This study consists of 2 steps. First step is a safety study of the intrathecal(IT) injection of "HYNR-CS inj" in 8 patients with ALS. In this phase 1 study, AE, laboratory test, physical examination, vital signs, Electrocardiogram, and Chest X-Ray examination were evaluated in terms of safety.

Second step is to compare the efficacy and safety between test group and control group of total 64 patients with ALS.


Options:
A: Arm Label: Test group; Type: EXPERIMENTAL; Interventions: Biological: HYNR-CS inj | Arm Label: Control group; Type: EXPERIMENTAL; Interventions: Other: Control group | Intervention Type: BIOLOGICAL; Name: HYNR-CS inj; Assigned to Arm(s): Test group | Intervention Type: OTHER; Name: Control group; Assigned to Arm(s): Control group
B: Arm Label: MSC-NTF cells IM; Type: EXPERIMENTAL; Interventions: Biological: MSC-NTF cells transplantation (IM) | Arm Label: MSC-NTF cells IT; Type: EXPERIMENTAL; Interventions: Biological: MSC-NTF cells transplantation (IT) | Intervention Type: BIOLOGICAL; Name: MSC-NTF cells transplantation (IM); Assigned to Arm(s): MSC-NTF cells IM | Intervention Type: BIOLOGICAL; Name: MSC-NTF cells transplantation (IT); Assigned to Arm(s): MSC-NTF cells IT
C: Arm Label: Treatment with autologous mesenchymal stem cells (MSC) intrathecally and intravenously; Type: EXPERIMENTAL; Interventions: Biological: Injection of autologous bone marrow derived mesenchymal stem cells | Intervention Type: BIOLOGICAL; Name: Injection of autologous bone marrow derived mesenchymal stem cells; Assigned to Arm(s): Treatment with autologous mesenchymal stem cells (MSC) intrathecally and intravenously
D: Arm Label: stem cell reciepient; Type: EXPERIMENTAL; Interventions: Biological: intrathecal injection | Intervention Type: BIOLOGICAL; Name: intrathecal injection; Assigned to Arm(s): stem cell reciepient

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pilot Roll Out of the Xpert MTB/Rif for the Diagnosis of Pulmonary Tuberculosis in Two Municipalities in Brazil: a Stepped Wedge Trial
Brief Summary: Diagnosis of tuberculosis (TB) is a challenge because sputum smear, the most rapid and inexpensive test, often fails to detect the disease, in around 20 to 30% of cases. Culture of sputum yields a correct diagnosis in up to 90% of cases, but results are only available in 4 to 8 weeks, depending on the method. A new test (Xpert MTB/Rif) based on a rapid technique, named polymerase chain reaction (PCR), detects TB in less than 2 hours over 95% of cases, in addition to identification of cases resistant to certain drugs used to treat TB. The test is expensive, but several studies have demonstrated its accuracy, and since most steps are automatized, savings can be expected from human resources work. The aims of our study are (1) to evaluate this tool as a substitute test for sputum smears in routine conditions; (2) evaluate if it is cost-effective, meaning that effectiveness of the test may outweigh the extra cost, and (3) evaluate the acceptability of the test among patients and health care workers.


Options:
A: Arm Label: Smear; Type: ACTIVE_COMPARATOR; Interventions: Other: Smear | Arm Label: GeneXpert; Type: EXPERIMENTAL; Interventions: Other: Xpert | Intervention Type: OTHER; Name: Xpert; Assigned to Arm(s): GeneXpert | Intervention Type: OTHER; Name: Smear; Assigned to Arm(s): Smear
B: Arm Label: Xpert MTB/Rif; Type: EXPERIMENTAL; Interventions: Other: Xpert MTB/Rif | Arm Label: Sputum smear; Type: ACTIVE_COMPARATOR; Interventions: Other: Smear microscopy | Intervention Type: OTHER; Name: Xpert MTB/Rif; Assigned to Arm(s): Xpert MTB/Rif | Intervention Type: OTHER; Name: Smear microscopy; Assigned to Arm(s): Sputum smear
C: Arm Label: Intervention; Type: OTHER; Interventions: Diagnostic Test: LF-LAM | Arm Label: Standard of care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIAGNOSTIC_TEST; Name: LF-LAM; Assigned to Arm(s): Intervention
D: Arm Label: Pulmonary Tuberculosis Suspects; Type: N/A; Interventions: Diagnostic Test: CRISPR-based Test | Intervention Type: DIAGNOSTIC_TEST; Name: CRISPR-based Test; Assigned to Arm(s): Pulmonary Tuberculosis Suspects

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pilot Roll Out of the Xpert MTB/Rif for the Diagnosis of Pulmonary Tuberculosis in Two Municipalities in Brazil: a Stepped Wedge Trial
Brief Summary: Diagnosis of tuberculosis (TB) is a challenge because sputum smear, the most rapid and inexpensive test, often fails to detect the disease, in around 20 to 30% of cases. Culture of sputum yields a correct diagnosis in up to 90% of cases, but results are only available in 4 to 8 weeks, depending on the method. A new test (Xpert MTB/Rif) based on a rapid technique, named polymerase chain reaction (PCR), detects TB in less than 2 hours over 95% of cases, in addition to identification of cases resistant to certain drugs used to treat TB. The test is expensive, but several studies have demonstrated its accuracy, and since most steps are automatized, savings can be expected from human resources work. The aims of our study are (1) to evaluate this tool as a substitute test for sputum smears in routine conditions; (2) evaluate if it is cost-effective, meaning that effectiveness of the test may outweigh the extra cost, and (3) evaluate the acceptability of the test among patients and health care workers.


Options:
A: Arm Label: Sputum induction; Type: EXPERIMENTAL; Interventions: Procedure: Sputum induction | Arm Label: No sputum induction; Type: ACTIVE_COMPARATOR; Interventions: Procedure: standard routine expectorated sputum | Intervention Type: PROCEDURE; Name: Sputum induction; Assigned to Arm(s): Sputum induction | Intervention Type: PROCEDURE; Name: standard routine expectorated sputum; Assigned to Arm(s): No sputum induction
B: Arm Label: Xpert MTB/Rif; Type: EXPERIMENTAL; Interventions: Other: Xpert MTB/Rif | Arm Label: Sputum smear; Type: ACTIVE_COMPARATOR; Interventions: Other: Smear microscopy | Intervention Type: OTHER; Name: Xpert MTB/Rif; Assigned to Arm(s): Xpert MTB/Rif | Intervention Type: OTHER; Name: Smear microscopy; Assigned to Arm(s): Sputum smear
C: Arm Label: Novel; Type: EXPERIMENTAL; Interventions: Procedure: GeneXpert MTB/RIF assay, Procedure: Smear microscopy | Arm Label: Standard; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Smear microscopy | Intervention Type: PROCEDURE; Name: GeneXpert MTB/RIF assay; Assigned to Arm(s): Novel | Intervention Type: PROCEDURE; Name: Smear microscopy; Assigned to Arm(s): Novel, Standard
D: Arm Label: Antiretroviral therapy, tuberculosis; Type: N/A; Interventions: N/A

Answer: B